Wnt Signaling in Bone

Takuo Kubota1,2, Toshimi Michigami2, and Keiichi Ozono1
1Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan
2Department of Bone and Mineral Research, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan

Abstract. Wnt signaling is involved not only in embryonic development but also in maintenance of homeostasis in postnatal tissues. Multiple lines of evidence have increased understanding of the roles of Wnt signaling in bone since mutations in the \textit{LRP5} gene were identified in human bone diseases. Canonical Wnt signaling promotes mesenchymal progenitor cells to differentiate into osteoblasts. The canonical Wnt/\beta\text{-}catenin pathway possibly through Lrp6, a co-receptor for Wnts as well as Lrp5, in osteoblasts regulates bone resorption by increasing the OPG/RANKL ratio. However, endogenous inhibitors of Wnt signaling including sclerostin block bone formation. Regulation of sclerostin appears to be one of the mechanisms of PTH anabolic actions on bone. Since sclerostin is almost exclusively expressed in osteocytes, inhibition of sclerostin is the most promising design. Surprisingly, Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum, but not by directly promoting bone formation. Pharmacological intervention may be considered in many components of the canonical Wnt signaling pathway, although adverse effects and tumorigenicity to other tissues are important. More studies will be needed to fully understand how the Wnt signaling pathway actually influences bone metabolism and to assure the safety of new interventions.

Key words: Wnt signaling, LRP5, LRP6, sclerostin, bone metabolism

Introduction

Bone mass increases in childhood and adolescence until it reaches the peak. Increasing the peak bone mass is important to prevent osteoporosis and fractures in later life, when bone mass gradually declines. Osteoporosis is defined as a skeletal disorder characterized by compromised bone strength predisposing to an increased risk of fracture, and it is a common health issue with the increasing size of our aging population (1). Genetic factors contribute to the variance in bone strength (2). Loss-of-function and gain-of-function mutations in the human \textit{low-density lipoprotein receptor-related protein 5} (\textit{LRP5}) gene have been shown to be associated with osteoporosis-pseudoglioma syndrome (OPPG) and high bone mass (HBM) phenotypes, respectively (3–5). A mutation in the \textit{LRP6} gene was recently identified in a family with risk factors of metabolic syndrome as well as osteoporosis (6). The above findings emphasize the importance of canonical Wnt signaling in bone metabolism because both LRP5
and LRP6 are thought to be co-receptors of Wnts (7–10). In this review, we describe roles of canonical Wnt signaling components in bone.

**Wnt Signaling**

Wnt molecules are a family of secreted cysteine-rich glycoproteins that activate at least three distinct pathways: the canonical (β-catenin-dependent), Ca$^{2+}$ and planar polarity pathways. Of the three, the canonical pathway has been well elucidated (11; http://www.stanford.edu/~rnusse/wntwindow.html). Briefly, in the absence of Wnts, β-catenin forms a complex with Axin, adenomatous polyposis coli (APC) and glycogen synthase kinase 3β (GSK-3β) and is phosphorylated by mainly GSK-3β, resulting in proteosomal degradation (Fig. 1A). Dickkopfs (Dkks), secreted frizzled-related proteins (Sfrps) and sclerostin are secreted Wnt inhibitors. When Wnts bind to Frizzled and LRP5 or LRP6 in a ternary complex at the cell surface, Axin is recruited away from the β-catenin destruction machine to LRP5 or LRP6, leading to the accumulation of β-catenin. Accumulated β-catenin translocates into the nucleus and activates LEF/TCF-mediated gene transcription. (Fig. 1B).
Wnt Signaling Components in Development and Disease

Wnt signaling is important in embryo development. Loss of a single Wnt gene can produce various phenotypes that range from embryonic lethality and central nerve system (CNS) abnormalities to kidney and limb defects (12) (Table 1). Some Wnts have a specific role in the developmental process, while others show redundancy in embryogenesis. That signaling is also involved in developing cancers and diseases, including colon cancer, coronary disease, tetra-amelia, Mullerian duct regression, eye vascular defects and abnormal bone mass (11) (Table 2).

Table 1  Roles of Wnt in mouse tissue development (Modified from ref. 12)

| Gene          | Knockout phenotypes                                                                 |
|---------------|------------------------------------------------------------------------------------|
| Wnt1, Wnt3a  | Defects in expansion of neural crest and CNS progenitors                            |
| Wnt1, Wnt4   | Decrease in thymocyte number                                                        |
| Wnt3a        | Paraxial mesoderm defects, tail bud defects                                         |
| Wnt4         | Absence of Mullerian duct, defects in adrenal gland development                    |
| Wnt5a        | Truncated limbs, defects in lung morphogenesis, chondrocytes differentiation defects |
| Wnt7a        | Abnormal development in females and regression failure of the Mullerian duct in males |
| Wnt7b        | Placental development defects, lung hypoplasia                                      |
| Wnt11        | Ureteric branching defects, kidney hypoplasia                                       |

Table 2  Wnt signaling components associated with human diseases (Modified from ref. 11)

| Gene   | Human disease                                                                                      |
|--------|---------------------------------------------------------------------------------------------------|
| WNT3   | LOF, tetra-amelia                                                                                  |
| WNT4   | LOF, Mullerian duct regression, virilization                                                      |
| SOST   | LOF, high bone mass, sclerosteosis, van Buchem disease                                              |
| LRP5   | GOF, high bone mass; LOF, osteoporosis-pseudoglioma syndrome, FEVR                                |
| LRP6   | LOF, osteoporosis, coronary disease, hypertension, diabetes, hyperlipidemia                        |
| FZD4   | LOF, FEVR                                                                                         |
| Axin2  | LOF, tooth agenesis, colorectal cancer                                                            |
| APC    | LOF, familial adenomatous polyposis, colorectal cancer                                              |
| /-catenin | GOF, colon cancer                                                                                     |

LOF, loss-of-function; GOF, gain-of-function; FEVR, familial exudative vitreoretinopathy; FZD, frizzled.

LRP5

Loss-of-function mutations in the LRP5 gene cause OOPG, a rare autosomal recessive disorder characterized by early onset osteoporosis and blindness (3). The patients display reduced bone mass and skeletal fragility. On the other hand, gain-of-function mutations in the LRP5 gene are associated with the autosomal dominant HBM phenotype (4, 5). Several association studies suggest that LRP5 polymorphisms are linked to bone mineral density (BMD) and fracture rate in the general population (13, 14). Recently, a genome-wide association study and a large-scale analysis have also demonstrated that LRP5 variants are associated with BMD and fracture risk (15, 16). Human bone phenotypes caused by LRP5 loss-of-function mutations are...
reproduced in mice lacking \textit{Lrp5} (17). \textit{Lrp5}^{-/-} mice exhibit a low bone mass and decreased proliferation of osteoblasts (bone forming cell). However, surprisingly, osteoblast-specific \textit{Lrp5} deficiency does not produce a low bone mass (18). \textit{Lrp5} has recently been shown to control bone formation by inhibiting serotonin synthesis in the duodenum (18). \textit{Lrp5} inhibits expression of tryptophan hydroxylase 1, the rate-limiting biosynthetic enzyme for serotonin in enterochromaffin cells of the duodenum. Serotonin acts in an endocrine fashion on osteoblasts through the serotonin receptor 1b and cAMP response element binding (CREB) protein, a transcription factor, to inhibit their proliferation (18). The above study in mice demonstrates that LRP5 in the gut but not bone regulates osteoblast proliferation.

\textbf{LRP6}

Mutant mice lacking \textit{Lrp6} display compound defects caused by mutations in various Wnt genes, including Wnt1, Wnt3a and Wnt7a (19), and die during the perinatal period. Heterozygosity for the \textit{Lrp6}-null allele further decreases BMD in mice lacking \textit{Lrp5} (20). We previously identified a point mutation, \textit{ringelschwanz} (\textit{rs}), in the \textit{Lrp6} gene in spontaneous missense mutant mice with delay in the appearance of ossification centers and reduced bone mass in adults (21). \textit{Lrp6}^{rs/rs} mice exhibit reduced trabecular bone mass associated with an expanded eroded (resorbed) surface (22). Urinary excretion of deoxypyridinoline, a bone resorption marker, is higher in \textit{Lrp6}^{rs/rs} mice, while the levels of serum osteocalcin, a bone formation marker, are unchanged between \textit{Lrp6}^{rs/rs} mice and wild-type littermates. Expression of the receptor activator of nuclear factor-\(\kappa\) B ligand (\textit{Rankl}), an essential molecule for the differentiation and activity of osteoclast (bone resorbing cell), is enhanced in \textit{Lrp6}^{rs/rs} osteoblasts both \textit{in vivo} and \textit{in vitro}, and osteoclastogenesis and bone-resorbing activity \textit{in vitro} are facilitated in \textit{Lrp6}^{rs/rs} cells (22). Taken together, \textit{Lrp6}-mediated signaling regulates bone mass, at least partly through the regulation of bone resorption. A study in humans demonstrated that a mutation in the \textit{LRP6} gene results in osteoporosis as well as early coronary disease, hyperlipidemia, hypertension and diabetes (7).

\textbf{Wnt}

\textit{Wnt} consists of 19 members (11); which of them are involved in bone metabolism has not been fully elucidated. Osteoblasts, chondrocytes, myocytes and adipocytes originate from mesenchymal stem cells. Adipogenesis is thought to be the default pathway for mesenchymal stem cells that do not receive an appropriate stimulation to differentiate into other cells. Wnt1 and Wnt10b inhibit adipogenesis in preadipocyte cells (23). Some Wnts, including Wnt7b and Wnt10b, have been shown to function in bone homeostasis in mice. Wnt7b is expressed in osteoblasts (24), and removal of \textit{Wnt7b} in skeletal progenitor cells in mice leads to defects in chondrogenesis and osteoblastogenesis (25). \textit{Wnt10b}^{-/-} mice have decreased trabecular bone with a reduced bone formation rate (26). The above results suggest that Wnt7b and Wnt10b are endogenous regulators of bone formation.

\textbf{\(\beta\)-Catenin}

\(\beta\)-Catenin plays different roles at various stages of osteoblast development. Deletion of \(\beta\)-catenin in mesenchymal precursors of chondrocytes (cartilage forming cells) and osteoblasts blocks osteoblast differentiation (27, 28). Thus, \(\beta\)-catenin is required for osteoblast differentiation in early stages. In osteoblasts, \(\beta\)-catenin plays another vital role. Inactivation of \(\beta\)-\textit{catenin} in osteoblasts using \textit{\alpha1} (I) collage-\textit{Cre} mice leads to low bone mass caused by increased bone resorption through enhanced expression of osteoprotegerin (\textit{Opg}), an antagonist for RANKL.
Deficiency of \(\beta\)-catenin in mature osteoblasts using osteocalcin-Cre mice produces severe osteopenia with increased osteoclasts (30). In vitro, osteoblasts lacking \(\beta\)-catenin exhibit elevated expression of Rankl and diminished expression of Opg (30). The above findings suggest that \(\beta\)-catenin in osteoblasts regulates osteoclastogenesis and osteoclast function.

**Wnt Inhibitors: Sclerostin, Dkk, Sfrp**

Sclerostin encoded by the *SOST* gene is a secreted Wnt antagonist. Several studies have shown that sclerostin binds to LRP5 and LRP6 to inhibit Wnt/\(\beta\)-catenin signaling (31, 32). Loss-of-function mutations and decreased expression of the *SOST* gene in humans are associated with sclerosteosis and van Buchem disease, respectively (33–35). Targeting and overexpressing of the *Sost* gene in mice lead to an increase and a reduction in bone mass with altered bone formation, respectively (36). Of note, sclerostin is almost exclusively expressed in osteocytes (37), which lie within the bone matrix and are derived from osteoblasts. Thus, sclerostin might be a promising therapeutic target molecule. Sclerostin monoclonal antibody treatment increases bone formation markers in postmenopausal women (38) and bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis (39). Intermittent administration of PTH stimulates bone formation, but the molecular and cellular mechanisms underlying this effect are not completely understood (40). PTH treatment reduces the expression of sclerostin (41, 42), possibly alleviating endogenous Wnt inhibition and enhancing bone formation. Transgenic mice expressing a constitutively active PTH receptor exclusively in osteocytes display increased bone mass (43). The above studies suggest that PTH receptor signaling in osteocytes affects bone metabolism, at least in part, by controlling sclerostin expression.

Dkks are also secreted glycoproteins. Dkk1, Dkk2 and Dkk4 inhibit Wnt/\(\beta\)-catenin signaling by binding to LRP5 and LRP6. *Dkk1*\(^{+/–}\) mice exhibit an HBM caused by an increase in bone formation (44). Mice overexpressing Dkk1 in osteoblasts develop osteopenia because of reduced osteoblast number and bone formation (45), indicating that Dkk1 negatively regulates bone formation. Unexpectedly, *Dkk2*\(^{−/−}\) mice are osteopenic with impaired mineralization (46). They exhibit enhanced osteoclastogenesis with the up-regulation of *Rankl* expression, indicating that Dkk2 affects both bone formation and bone resorption. Sfrps are Wnt antagonists that block the interaction between Wnts and frizzled receptors, and adult *Sfrp1*\(^{−/−}\) mice exhibit an increase in trabecular bone accrual (47).

**Conclusion**

A wide variety of findings have revealed that canonical Wnt signaling plays crucial roles in bone. It favors the commitment of mesenchymal progenitor cells to osteoblasts and also regulates bone resorption by increasing the OPG/RANKL ratio in osteoblasts. Wnt inhibitors including sclerostin mainly block bone formation. Inhibition of sclerostin might be the most promising therapeutic design to augment bone mass. Surprisingly, Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum, but not by directly promoting bone formation. More studies will be needed to fully understand how the Wnt signaling pathway actually controls bone metabolism.

**Acknowledgements**

This work was supported in part by Grants-in-Aid from the Research Society for Metabolic Bone Diseases (to K.O.).

**References**

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy.
2. Liu YJ, Shen H, Xiao P, Xiong DH, Li LH, Recker RR, et al. Molecular genetic studies of gene identification for osteoporosis: a 2004 update. J Bone Miner Res 2006;21:1511–35.

3. Gong Y, Slee RB, Fukui N, Rawadi G, Roman-Roman S, Regnato AM, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001;107:513–23.

4. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002;346:1513–21.

5. Little RD, Carulli JR, Del Mastro RG, Dupuis J, Osborne M, Folz C, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002;70:11–9.

6. Mani A, Radhakrishnan J, Wang H, Mani A, Mani M-A, Nelson-Williams C, et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007;315:1278–82.

7. Khosla S, Westendorf JJ, Oursler MJ. Building bone to reverse osteoporosis and repair fractures. J Clin Invest 2008;118:421–8.

8. Williams BO, Insogna KL. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone. J Bone Miner Res 2009;24:171–8.

9. Kubota T, Michigami T, Ozono K. Wnt signaling in bone metabolism. J Bone Miner Metab 2009;27:265–71.

10. Warden SJ, Robling AG, Haney EM, Turner CH, Bliziotis MM. The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5). Bone 2009;46:4–12.

11. MacDonald BT, Tamai K, He X. Wnt/β-Catenin signaling: components, mechanisms, and diseases. Dev Cell 2009;17:9–26.

12. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781–810.

13. Balemans W, Van Hul W. The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes. Endocrinology 2007;148:2622–9.

14. Ezura Y, Nakajima T, Urano T, Sudo Y, Kajita M, Yoshida H, et al. Association of a single-nucleotide variation (A1330V) in the low-density lipoprotein receptor-related protein 5 gene (LRP5) with bone mineral density in adult Japanese women. Bone 2007;40:997–1005.

15. Richards JB, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N, Wilson SG, et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 2008;371:1505–12.

16. van Meurs JB, Trikalinos TA, Ralston SH, Balcells S, Brandi ML, Brixen K, et al. GENOMOS Study. Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA 2008;299:1277–90.

17. Kato M, Patel MS, Levasseur R, Lobov I, Chang BHJ, Glass 2nd DA, et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 2002;157:303–14.

18. Yadav VK, Ryu JH, Suda N, Tanaka KP, Gingrich JA, Schütz G, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008;135:825–37.

19. Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC. An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 2000;407:535–8.

20. Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH, Hess JF, et al. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res 2004;19:2033–40.

21. Kokubu C, Heinzmann U, Kokubu T, Sakai N, Kubota T, Kawai M, et al. Skeletal defects in ringelschwanz mutant mice reveal that Lrp6 is required for proper somitogenesis and osteogenesis. Development 2004;131:5469–80.

22. Kubota T, Michigami T, Sakaguchi N, Kokubu C, Suzuki A, Namba N, et al. Lrp6 Hypomorphic Mutation Affects Bone Mass through Bone Resorption in Mice and Impairs Interaction with Mesd. J Bone Miner Res 2008;23:1661–71.

23. Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL, et al. Inhibition of adipogenesis by Wnt signaling. Science
Wnt/LRP6 and LRP5 signaling and bone development.

24. Hu H, Hilton MJ, Tu X, Yu K, Ornitz DM, Long F. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 2005;132:49–60.

25. Tu X, Joeng KS, Nakayama KI, Nakayama K, Rajagopal J, Carroll TJ, et al. Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone formation. Dev Cell 2007;12:113–27.

26. Bennett CN, Ouyang H, Ma YL, Zeng Q, Gerin I, Sousa KM, et al. Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J Bone Miner Res 2007;22:1924–32.

27. Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005;8:739–50.

28. Hill TP, Später D, Taketo MM, Birchmeier W, Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 2005;8:727–38.

29. Glass 2nd DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005;8:751–64.

30. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere M-C, Bouxsein ML, et al. Essential Role of beta-catenin in postnatal bone acquisition. J Biol Chem 2005;280:21162–8.

31. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005;280:19883–7.

32. Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 2005;280:26770–5.

33. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001;10:537–43.

34. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001;68:577–89.

35. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002;39:91–7.

36. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D’Agostin D, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008;23:860–9.

37. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005;19:1842–4.

38. Padhi D, Stouch B, Jang G, Pang L, Darling M, Glise H, et al. Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women. J Bone Miner Res 2007;22:S37.

39. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009;24:578–88.

40. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007;40:1434–46.

41. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O’Brien CA, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005;146:4577–83.

42. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone 2005;37:148–58.

43. O’Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE 2008;3:e2942.

44. Morvan F, Boulukos K, Clément-Lacroix P, Roman Roman S, Suc-Royer I, Vayssière B, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006;21:934–45.
45. Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 2006;39:754–66.

46. Li X, Liu P, Liu W, Maye P, Zhang J, Zhang Y, et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation.

47. Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert AJ, Goad MB, et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol 2004;18:1222–37.